Drugs / OCADUSERTIB
OCADUSERTIB
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT06049108 | Sep → Nov 2023 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT05960851 | Aug → Oct 2023 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT05602675 | Nov 2022 → Mar 2023 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT05222399 | Feb → Mar 2022 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05848258 | May 2023 → Dec 2025 | rheumatoid arthritis | Eli Lilly and Company | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OCADUSERTIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL5416250 ↗ |
| Known as | LY3871801 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05602675 ↗ |
| Known as | R-552 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5416250 ↗ |
| Modality | Small molecule | — CHEMBL5416250 ↗ |
| Route | Oral | “Administered orally.” NCT05222399 ↗ |